Lingyun Hu1, Ashley Aronow2, Lakshmi Raj2, Erica C. Henning1
1Global Imaging Group, Novartis Institutes for Biomedical Research (NIBR), Cambridge, MA, United States; 2Biologics Center, Novartis Institutes for Biomedical Research (NIBR), Cambridge, MA, United States
In this study, we employed combined MDEFT/RARE for non-invasive, longitudinal monitoring of HCC progression with high sensitivity and reliability. We were able to diagnose and quantify primary HCC tumor volume and secondary liver metastasis without contrast agent and without respiratory triggering. We achieved higher CNR than previous reports employing Gd-DTPA or Gd-EOB-DTPA, with a detection limit of 1mm diameter HCC versus 2mm reported. With easy setup and no contrast agent or respiratory triggering required, MDEFT/RARE provides a powerful alternative for accurate quantification of HCC, with relatively high throughput, improved study power, and reduction in animal use.